Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence - PubMed (original) (raw)
Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence
James P Boyle et al. Popul Health Metr. 2010.
Abstract
Background: People with diabetes can suffer from diverse complications that seriously erode quality of life. Diabetes, costing the United States more than $174 billion per year in 2007, is expected to take an increasingly large financial toll in subsequent years. Accurate projections of diabetes burden are essential to policymakers planning for future health care needs and costs.
Methods: Using data on prediabetes and diabetes prevalence in the United States, forecasted incidence, and current US Census projections of mortality and migration, the authors constructed a series of dynamic models employing systems of difference equations to project the future burden of diabetes among US adults. A three-state model partitions the US population into no diabetes, undiagnosed diabetes, and diagnosed diabetes. A four-state model divides the state of "no diabetes" into high-risk (prediabetes) and low-risk (normal glucose) states. A five-state model incorporates an intervention designed to prevent or delay diabetes in adults at high risk.
Results: The authors project that annual diagnosed diabetes incidence (new cases) will increase from about 8 cases per 1,000 in 2008 to about 15 in 2050. Assuming low incidence and relatively high diabetes mortality, total diabetes prevalence (diagnosed and undiagnosed cases) is projected to increase from 14% in 2010 to 21% of the US adult population by 2050. However, if recent increases in diabetes incidence continue and diabetes mortality is relatively low, prevalence will increase to 33% by 2050. A middle-ground scenario projects a prevalence of 25% to 28% by 2050. Intervention can reduce, but not eliminate, increases in diabetes prevalence.
Conclusions: These projected increases are largely attributable to the aging of the US population, increasing numbers of members of higher-risk minority groups in the population, and people with diabetes living longer. Effective strategies will need to be undertaken to moderate the impact of these factors on national diabetes burden. Our analysis suggests that widespread implementation of reasonably effective preventive interventions focused on high-risk subgroups of the population can considerably reduce, but not eliminate, future increases in diabetes prevalence.
Figures
Figure 1
Incident cases of diagnosed diabetes per 1,000 people, 1980-2007, and three scenarios for projected cases per 1,000, 2008 -2050: a middle scenario (posterior means) and low and high scenarios (lower and upper limits of 95% Bayesian confidence intervals) from the projection model of diagnosed diabetes incidence.
Figure 2
Projections of total diabetes prevalence as a percentage of the total US adult population for four scenarios: low incidence projections and r1 = 1.77, r2 = 2.11; low incidence projections and r1 = 1.00, r2 = 4.08; middle incidence projections and r1 = 1.77, r2 = 2.11; middle incidence projections and r1 = 1.00, r2 = 4.08.
Similar articles
- Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030.
Gregg EW, Boyle JP, Thompson TJ, Barker LE, Albright AL, Williamson DF. Gregg EW, et al. Popul Health Metr. 2013 Sep 18;11(1):18. doi: 10.1186/1478-7954-11-18. Popul Health Metr. 2013. PMID: 24047329 Free PMC article. - Tuberculosis.
Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P. Bloom BR, et al. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review. - Prevalence and Incidence of Type 2 Diabetes and Prediabetes.
Cowie CC, Casagrande SS, Geiss LS. Cowie CC, et al. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd edition. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018 Aug. CHAPTER 3. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd edition. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018 Aug. CHAPTER 3. PMID: 33651562 Free Books & Documents. Review. - Implications of population growth on prevalence of diabetes. A look at the future.
Helms RB. Helms RB. Diabetes Care. 1992 Mar;15 Suppl 1:6-9. doi: 10.2337/diacare.15.1.s6. Diabetes Care. 1992. PMID: 1559424 - Projection of the future diabetes burden in the United States through 2060.
Lin J, Thompson TJ, Cheng YJ, Zhuo X, Zhang P, Gregg E, Rolka DB. Lin J, et al. Popul Health Metr. 2018 Jun 15;16(1):9. doi: 10.1186/s12963-018-0166-4. Popul Health Metr. 2018. PMID: 29903012 Free PMC article.
Cited by
- Novel variations in the adiponectin gene (ADIPOQ) may affect distribution of oligomeric complexes.
Kottyan LC, Woo JG, Keddache M, Banach W, Crimmins NA, Dolan LM, Martin LJ. Kottyan LC, et al. Springerplus. 2012 Dec;1(1):66. doi: 10.1186/2193-1801-1-66. Epub 2012 Dec 14. Springerplus. 2012. PMID: 23396303 Free PMC article. - Agent-Based Modeling of Chronic Diseases: A Narrative Review and Future Research Directions.
Li Y, Lawley MA, Siscovick DS, Zhang D, Pagán JA. Li Y, et al. Prev Chronic Dis. 2016 May 26;13:E69. doi: 10.5888/pcd13.150561. Prev Chronic Dis. 2016. PMID: 27236380 Free PMC article. Review. - Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment.
Myakala K, Jones BA, Wang XX, Levi M. Myakala K, et al. Am J Physiol Renal Physiol. 2021 Jun 1;320(6):F1133-F1151. doi: 10.1152/ajprenal.00614.2020. Epub 2021 Apr 19. Am J Physiol Renal Physiol. 2021. PMID: 33870733 Free PMC article. - Economic Evaluation of Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force.
Li R, Qu S, Zhang P, Chattopadhyay S, Gregg EW, Albright A, Hopkins D, Pronk NP. Li R, et al. Ann Intern Med. 2015 Sep 15;163(6):452-60. doi: 10.7326/M15-0469. Ann Intern Med. 2015. PMID: 26167962 Free PMC article. Review. - Relationships of the Mediterranean dietary pattern with insulin resistance and diabetes incidence in the Multi-Ethnic Study of Atherosclerosis (MESA).
Abiemo EE, Alonso A, Nettleton JA, Steffen LM, Bertoni AG, Jain A, Lutsey PL. Abiemo EE, et al. Br J Nutr. 2013 Apr 28;109(8):1490-7. doi: 10.1017/S0007114512003339. Epub 2012 Aug 30. Br J Nutr. 2013. PMID: 22932232 Free PMC article.
References
- Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin JM, Gregg EW, Tierney EF, Rios-Burrows N, Mokdad AH, Ford ES, Imperatore G, Narayan KMV. The evolving diabetes burden in the United States. Ann Intern Med. 2004;140:945–950. - PubMed
- American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;32:596–615. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources